JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JVI Accepts, published online ahead of print on 28 February 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.02564-06v1
81/10/5225    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malhotra, U.
Right arrow Articles by McElrath, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malhotra, U.
Right arrow Articles by McElrath, M. J.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.02564-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Enhanced Detection of HIV-1 Nef-Specific T-cells Recognizing Multiple Variants in Early HIV-1 Infection

Uma Malhotra*, Fusheng Li, Jessica Nolin, Megan Allison, Hong Zhao, James I. Mullins, Steve Self, and M. Juliana McElrath

Program in Infectious Diseases, Clinical Research Division, and the Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., D3-100, Seattle, WA, 98109, USA; Department of Medicine, Department of Microbiology, and Department of Laboratory Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195, USA

* To whom correspondence should be addressed. Email: uma{at}u.washington.edu.


   Abstract

Background: A preventive HIV vaccine will likely need to induce broad immunity that can recognize antigens expressed within circulating strains. To understand the potentially relevant responses that T-cell based vaccines should elicit, we examined the ability of T cells from early-infected persons to recognize a broad spectrum of potential T-cell epitopes (PTE) expressed by the products encoded by HIV-1 nef, which is commonly included in candidate vaccines. Methods: T cells were evaluated for IFN-{gamma}-secretion using two peptide panels: subtype B consensus (CON) peptides and a novel peptide panel providing 70% coverage of PTE in subtype B HIV-1 Nef. Results: Eighteen of 23 subjects' T cells recognized HIV-1 Nef. In one subject, Nef-specific T cells were detected with the PTE, but not the CON peptides. The greatest frequency of responses spanned Nef amino acids 65-103 and 113 -147, with multiple epitope variants being recognized. Detection of both the epitope domain number and response magnitude were enhanced using the PTE peptides. On average, we detected 2.7 epitope domains with the PTE versus 1.7 domains with CON peptides (P=0.0034). The average response magnitude was 2,169 SFC/106 PBMC with the PTE versus 1,010 SFC/106 PBMC with CON peptides (P=0.0046). Conclusions: During early HIV-1 infection, Nef-specific T cells capable of recognizing multiple variants are commonly induced; and these responses are readily detected with the PTE peptide panel. Our findings suggest that Nef responses induced by a given vaccine strain before HIV-1 exposure may be sufficiently broad to recognize most variants within subtype B HIV-1.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.